Drotrecogin alfa (activated) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Drotrecogin alfa (activated) + Placebo
Drotrecogin alfa (activated) + Placebo is a phase 3 stage product being developed by Eli Lilly for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00049764. Target conditions include Sepsis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00604214 | Phase 3 | Completed |
| NCT00190788 | Phase 3 | Completed |
| NCT00049764 | Phase 3 | Completed |
| NCT00568737 | Phase 3 | Completed |
Competing Products
20 competing products in Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alkaline Phosphatase + Placebo | AM-Pharma | Phase 2 | 44 |
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 52 |
| Meropenem | Pfizer | Approved | 84 |
| Imipenem | Merck | Approved | 85 |
| Cefiderocol | Shionogi | Phase 1 | 33 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 77 |
| E5564 | Eisai | Phase 2 | 52 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 85 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| sPLA2 Inhibitor | Eli Lilly | Phase 1/2 | 41 |
| Drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD4144 + Placebo | AstraZeneca | Phase 2 | 52 |